The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Prescription medicines (139)
- (-) Legislation (81)
- (-) Complementary medicines (33)
- Advertising (248)
- Medicine safety (159)
- COVID-19 (144)
- Regulatory compliance (128)
- COVID-19 vaccines (88)
- Therapeutic goods regulation (75)
- Listed medicines (54)
- Non-prescription medicines (50)
- Safety (48)
- Medical devices safety (43)
- Vaping hub (39)
- Manufacturing (33)
- Labelling and packaging (28)
- Assessed listed medicines (26)
- Over the counter (OTC) medicines (25)
- Scheduling (national classification system) (24)
- Australian Register of Therapeutic Goods (ARTG) (22)
- Compliance and enforcement hub (22)
- Medicinal cannabis hub (21)
- Import and export (19)
- Alert/Advisory (18)
- Shortages (12)
- In Vitro Diagnostic medical devices (IVDs) (11)
- Sunscreens (8)
- Weight loss products (8)
- Advisory bodies and committees (5)
- Clinical trials (3)
- Cosmetics (3)
- Blood and blood components (2)
- Fees and payments (2)
- Prescription opioids hub (2)
- Registered complementary medicines (2)
- Unique Device Identification (UDI) hub (2)
- Advanced therapies (1)
- Biological medicines (1)
- Blood safety (1)
- Breast implant hub (1)
- Travelling with health products (1)
Search
237 result(s) found, displaying 1 to 25
-
Compliance undertakingsWe have accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd, regarding advertising of prescription-only compounded medicines for weight-loss.
-
NoticesUpdate on the progress in reducing the backlog of GMP Clearance Compliance Verification (CV) applications.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
NoticesThis instrument is made under subsection 7C(1) of the Therapeutic Goods Act 1989.
-
NewsThe updated plan emphasises solidifying our collaborative processes, aligning expectations with industry, and improving our communication strategies.
-
NewsFollowing a request from the sponsor to reconsider their decision, the TGA has confirmed the initial decision to not register the medicine on the basis that the safety and efficacy of the medicine were not satisfactorily established.
-
NoticesListed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 1) 2025, which commenced on 1 March 2025
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
NoticesThis consent is given under sections 14 and 14A of the Therapeutic Goods Act 1989.
-
NoticesThis instrument is made under subsections 19(5AA), 32CM(1A) and 41HC(1A) of the Therapeutic Goods Act 1989.
-
Therapeutic Goods (Special Access Scheme - Application and Notification Forms) Approval (No. 2) 2024
NoticesThis instrument is made under the Therapeutic Goods Regulations 1990, the Therapeutic Goods (Medical Devices) Regulations 2002 and the Therapeutic Goods Act 1989. -
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
NoticesMRA GMP clearances that are expiring on 31 December 2024 will be automatically extended.
-
NewsFind out about new requirements for labels of injectable electrolyte medicines and updates to guidance for medicine sponsors.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Media releasesThe TGA has settled judicial review proceedings brought by InstantScripts in respect of infringement notices issued to it by the TGA.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
NewsThe TGA is updating information for nitrosamine impurities in medicines including acceptable intakes (AI).
-
NewsTGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).
-
NewsFollowing our Essential Principles presentations on 11-12 September 2024, we have collated questions asked into themes to simplify finding information of relevance to you.
-
NewsThe Prescription Medicines in Pregnancy database has been updated to include new and amended entries.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
NoticesFind out how listed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 3) which commenced on 27 September 2024.
-
Media releasesWe have issued an infringement notice to the New South Wales based company for the alleged supply of a complementary medicine that was missing a mandatory warning statement.